Login
Register
Questions
Unanswered
Tags
Categories
Ask a Question
Search
EconTrack
About EconSpark
Ask a Question
Recent questions tagged fda
0
votes
0
answers
10
views
Design/Conduct of Externally Controlled Trials for Drug/Biological Products draft guidance--FDA seeks comments (by 5/2)
asked
7 hours
ago
by
Andrew Reamer
(
38.6k
points)
fda
clinical-trials
drugs
0
votes
0
answers
61
views
Quantitative Research on Front-of-Package Labeling on Packaged Foods--FDA invites comment (by 3/27)
asked
6 days
ago
by
Andrew Reamer
(
38.6k
points)
fda
food-labeling
0
votes
0
answers
119
views
Dosage/Administration Labeling for Prescription Drugs -- FDA invites comments on draft guidance (by 3/14)
asked
19 days
ago
by
Andrew Reamer
(
38.6k
points)
fda
prescription-drugs
0
votes
0
answers
157
views
Joint USPTO-FDA Collaboration Initiatives -- public listening session (1/19), comments invited (2/6)
asked
2 months
ago
by
Andrew Reamer
(
38.6k
points)
uspto
fda
0
votes
0
answers
328
views
2023 Drug Supply Chain Security Act Implementation/Readiness Efforts -- FDA holds mtg (12/7-8), seeks input (by 2/6)
asked
2 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-supply-chain
0
votes
0
answers
82
views
FDA: Advancing Premarket Safety Analytics -- comments invited (by 12/5)
asked
2 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
0
votes
0
answers
124
views
Drugs Distributed Manufacturing and Point-of-Care Manufacturing -- FDA seeks comments (by 12/13)
asked
3 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-manufacturing
0
votes
0
answers
186
views
FDA Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot -- comments invited on design (by 1/10)
asked
3 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
medical-devices
0
votes
0
answers
104
views
Human Nonprescription Drug Product Labeling Content/Format -- FDA invites comment on draft industry guidance (by 11/8)
asked
4 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
nonprescription-drugs
0
votes
0
answers
115
views
Evaluation of Therapeutic Equivalence -- FDA invites comment on draft industry guidance (by 9/19)
asked
6 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drugs
0
votes
0
answers
145
views
Drug Supply Chain Security Act: Drug Tracing Info Exchange Stds -- FDA proposes industry guidance (comment by 9/6)
asked
6 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-supply-chain
0
votes
0
answers
182
views
Drug Supply Chain Security Act: Identifying Trading Partners -- FDA proposes industry guidance (comment by 9/6)
asked
6 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-supply-chain
0
votes
0
answers
479
views
Patient-Focused Drug Development -- Guidance 3 for industry -- FDA invites comments on draft (by 9/28)
asked
7 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-development
0
votes
0
answers
477
views
Nonprescription Drug Product w/ Additional Condition for Nonprescription Use -- FDA invites input on rule (by 11/25)
asked
7 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
nonprescription-drugs
0
votes
0
answers
537
views
Drug Quality Risk Management -- FDA invites comments on draft ICH guidance for industry (by 7/15)
asked
7 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drugs
0
votes
0
answers
171
views
Prescription Drug Promotion Research -- FDA invites comments on proposed tradeoff analysis (by 6/24)
asked
9 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
prescription-drugs
0
votes
0
answers
515
views
FDA Quality Metrics Reporting Program -- comments invited on proposed changes (by 6/7)
asked
10 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
quality-metrics-drug-manufacturing
0
votes
0
answers
286
views
Drug Supply Chain Security Act -- FDA invites comment on 2 draft rules on wholesale distributors (by 4/5 and 9/6)
asked
11 months
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-supply-chain
0
votes
0
answers
504
views
Drug Supply Chain Security Act illegitimate product notification - FDA invites comments to OMB on proposal (by 2/25)
asked
1 year
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-supply-chain
0
votes
0
answers
194
views
FDA Guidance for Industry: Data Standards for Drug/Biological Product Submissions -- comments on draft invited (by 2/4)
asked
1 year
ago
by
Andrew Reamer
(
38.6k
points)
fda
0
votes
0
answers
249
views
FDA Guidance for Industry on Use of EHRs/Med Claims to Support Reg Decisions -- comments invited on draft (by 1/24)
asked
1 year
ago
by
Andrew Reamer
(
38.6k
points)
fda
electronic-health-records
medical-claims
evidence
0
votes
0
answers
278
views
FDA Guidance for Industry on Use of Data/Evidence to Support Reg Decisions -- comments invited on draft (by 3/9)
asked
1 year
ago
by
Andrew Reamer
(
38.6k
points)
fda
evidence
0
votes
0
answers
382
views
FDA Guidance for Industry on Assessing Registries to Support Reg Decisions -- comments invited on draft (by 2/28)
asked
1 year
ago
by
Andrew Reamer
(
38.6k
points)
fda
drugs
0
votes
0
answers
416
views
Enhancing Safety/Security of Pharma Distribution Supply Chain -- FDA public mtg (11/16), seeks comments (by 1/18)
asked
1 year
ago
by
Andrew Reamer
(
38.6k
points)
fda
drug-supply-chain
prescription-drugs
0
votes
0
answers
291
views
Health economists -- FDA Office of Women's Health seeks input on strategic research priorities (by 9/8)
asked
2 years
ago
by
Andrew Reamer
(
38.6k
points)
fda
womens-health
To see more, click for the
full list of questions
or
popular tags
.
...